This activity is designed to update physicians on the most clinically impactful data presented at the 2016 Genitourinary Cancers Symposium so that they can assess and prepare to apply these findings to their clinical practice to improve patient care.
Instructions For This Activity & Receiving Credit
This educational program is directed toward all attendees of the 2016 Genitourinary Cancers Symposium including medical, surgical, and radiation oncologists and urologists involved in the treatment of patients with GU malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other health care professionals, interested in the treatment of GU malignancies, may also participate.
Daniel P Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT
Disclosure: Grant/Research Support: Bayer, Bellicum Pharmaceuticals, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Millennium Pharmaceuticals, Medivation, Pfizer, Roche Laboratories, Tyme, Inc. Consultant: Bayer, Bellicum Pharmaceuticals, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Millennium Pharmaceuticals, Medivation, Pfizer, Roche Laboratories, Tyme, Inc.
Primo N Lara, Jr, MD
Professor of Medicine
Associate Director for Translational Research
UC Davis Comprehensive Cancer Center
Disclosure: Honoraria: Pfizer. Consulting/Advisory Role: Clovis Oncology, Pfizer, Teva Pharmaceutical, Halozyme Therapeutics, Novartis, Sanofi, Lpath, Lilly, AstraZeneca, Bayer, Genentech/Roche. Research Funding: Millennium, Polaris, OncoGenex Pharmaceuticals, GlaxoSmithKline, Genentech, Aragon Pharmaceuticals, Janssen Biotech, Heat Biologics.
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY